BOLD

Boundless Bio is a clinical-stage oncology company with no product revenue in any year shown (FY2023–FY2025 revenue is blank) and an accumulated deficit of -$260M. The entire investment case rests on its extrachromosomal-DNA-directed therapeutic candidates (ecDTx): the 10-K's forward-looking language is dominated by 'the timing and likelihood of success' of clinical trials, 'initial clinical data readout,' and whether cash 'will be sufficient to fund achievement of milestones.' There is no efficacy data in the provided figures to underwrite that, which makes the outcome genuinely unknowable — the defining trait of an 'avoid' for a self-directed retail holder.

The balance sheet is the one point of comfort and the reason conviction is not higher on the downside. At $2.50 on 22.4M shares the market cap is roughly $56M, versus stockholders' equity of $98.7M (≈0.57x book) and current assets of $110M against just $12.5M of current liabilities. Reported cash is only $17.9M, but the $110M current-asset base implies the balance sheet is padded with short-term investments, and operating cash burn of -$46.7M/yr points to roughly two years of runway before dilutive financing is required. Liabilities/equity of 0.59x is not stressed. So the company is not on the brink — it is cheap relative to its own net assets — but the retained deficit is still widening and equity fell 34.5% year over year.